Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs
暂无分享,去创建一个
[1] Jong-In Park,et al. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells , 2017, Cancer biology & therapy.
[2] A. Lyakhovich,et al. Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy , 2015, Oxidative medicine and cellular longevity.
[3] L. Mishra,et al. EMT, CTCs and CSCs in tumor relapse and drug-resistance , 2015, Oncotarget.
[4] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[5] Yau-Huei Wei,et al. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma , 2015, Cell cycle.
[6] M. Kreissl,et al. Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Villarroya,et al. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. , 2013, Human molecular genetics.
[8] P. Oliveira,et al. Mitochondria in cancer stem cells: a target for therapy. , 2013, Recent patents on endocrine, metabolic & immune drug discovery.
[9] Christina Yau,et al. Ageing, oxidative stress and cancer: paradigms in parallax , 2008, Nature Reviews Cancer.
[10] M. Schlumberger,et al. Management of advanced medullary thyroid cancer. , 2016, The lancet. Diabetes & endocrinology.